New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis
New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis
复制标题
DOI：
10.1177/135245850000600305
复制
发表时间：
2000-06-01
影响因子：
5.8
通讯作者：
Maguire, MG
中科院分区：
文献类型：
--
作者：
Balcer, LJ;Baier, ML;Maguire, MG
多发性硬化症 (MS) 临床试验中视功能的定量评估仅限于 Snellen 视力。本研究的目的是检查多发性硬化症患者和无视觉症状志愿者的新视觉结果测量（低对比度斯隆字母表）的评估者间可靠性和测试特征。由两名独立评估者测量四个对比度级别（100、5、1.25 和 0.6%）中的每一个的对比度字母敏锐度分数（字母分数）。评估者间的一致性通过组内相关系数（ICC）和平均分数的比较来描述。 MS 患者 (n=100) 和视觉上无症状志愿者 (n=33) 的每个对比水平均表现出出色的评估者间一致性 (ICC=0.86-0.95)。 MS 组中最低对比度水平 (0.6%) 的平均字母评分差异很大，即使在视力为 20/20 或更好的患者以及不需要行走帮助的患者中也是如此。低对比度斯隆字母图测试是一种高度可靠的视觉评估方法，可提供斯内伦视力或行走状态无法捕获的多发性硬化症神经损伤方面的信息。这种新方法展示了作为未来多发性硬化症临床试验的视觉功能结果测量的巨大潜力。
The quantitative assessment of visual function in multiple sclerosis (MS) clinical trials has been limited to Snellen visual acuity. The purpose of this study was to examine the inter-rater reliability and test characteristics of a new visual outcome measure, the Low-Contrast Sloan Letter Charts, in Patients with MS and visually-asymptomatic volunteers. Contrast letter acuity scores (letter scores) were measured or each of four contrast levels (100, 5, 1.25 and 0.6%) by two independent raters. Inter-rater agreement was described with the intraclass correlation coefficient (ICC) and comparison of mean scores. Excellent inter-rater agreement (ICC=0.86-0.95) was demonstrated at each contrast level among MS Patients (n=100) and visually-asymptomotic volunteers (n=33). Average letter scores at the lowest contrast level (0.6%) were highly variable in the MS group, even among patients with visual acuities of 20/20 or better, and among those who required no assistance for ambulation. Low-Contrast Sloan Letter Chart testing is a highly reliable method of visual assessment, and Provides information on on aspect of neurologic impairment in MS which is not captured by Snellen visual acuity or ambulation status. This new method demonstrates excellent Potential as a visual function outcome measure for future MS clinical trials.